drugset / Trial / NCT05537402
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
Phase 2
Terminated
1 enrolled
University of Texas Southwestern Medical Center
Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarterial chemoembolization (TACE) or transarterial radioembolization (TARE).
Timeline
- Start
- 2023-09-27
- Primary completion
- 2025-06-06
- Completion
- 2025-06-06
Outcome
Outcome not reported
Stopped (Enrollment): “The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |